RT Journal Article
SR Electronic
T1 Comorbidity trajectories before and after the diagnosis of heart failure: a UK Biobank cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.28.24312712
DO 10.1101/2024.08.28.24312712
A1 MacGowan, Hugo
A1 Brown, Oliver I
A1 Drozd, Michael
A1 Walker, Andrew MN
A1 Giannoudi, Marilena
A1 Straw, Sam
A1 Paton, Maria F
A1 Gierula, John
A1 McGinlay, Melanie
A1 Griffin, Kathryn J
A1 Witte, Klaus K
A1 Kearney, Mark T
A1 Cubbon, Richard M
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.28.24312712.abstract
AB Background Heart Failure (HF) is frequently associated with multiple comorbidities. We aimed to define their trajectory of accrual to identify opportunities for disease prevention.Methods We identified all participants in the UK Biobank cohort study diagnosed with HF prior to enrolment or during follow-up, who had disease occurrence data available from both primary and secondary care records (n=9,824). We established the time between diagnosis of HF and 16 common comorbidities to determine the rate and sequence of comorbidity accrual in relation to HF. Stratified analyses considered associations with sex and age at diagnosis of HF.Findings In chronological sequence, HF was the median fourth diagnosis for men and women. As the age at HF diagnosis increased, HF came later in the sequence of diseases (median second in under 50s to fifth in those aged 80-90). In all age strata, comorbidities accumulated for over a decade before HF and this accelerated in the years immediately before HF. The median time between comorbidity and HF diagnoses ranged from depression preceding HF by 10.7 years to dementia proceeding HF by 0.7 years; all comorbidities presented earlier in women. Atrial fibrillation/flutter was the commonest disease to immediately precede HF, followed by hypertension, cancer, myocardial infarction and osteoarthritis.Interpretation HF is most often diagnosed in people with established multimorbidity. There is a protracted window of opportunity during which interventions to prevent HF could be applied, often in disease contexts where this is not routine care, such as cancer and osteoarthritis.Funding British Heart Foundation (RG/F/22/110076)Competing Interest StatementSS has received speakers fees honoraria and non-financial support from Astra Zeneca. MFP has received consultancy fees from Astra Zeneca. RC has received speakers fees from Janssen Oncology.Funding StatementThis study was funded by the British Heart Foundation (RG/F/22/110076)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Service of UK National Health Service approved UK Biobank via application 11/NW/0382.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank data are available via application at https://www.ukbiobank.ac.uk